tiprankstipranks
Advertisement
Advertisement

IONS Stock Latest News

Ionis: Bepirovirsen Data Reinforce Underappreciated Partnered Pipeline; Buy Rating and $110 Price Target Reiterated
RatingsIonis: Bepirovirsen Data Reinforce Underappreciated Partnered Pipeline; Buy Rating and $110 Price Target Reiterated
6d ago
IONS
Ionis Gains on Positive Phase 3 Hepatitis B Data
PremiumCompany Announcements
Ionis Gains on Positive Phase 3 Hepatitis B Data
7d ago
8K
IONS
Ionis Pharmaceuticals: Advancing Pipeline, HBV Phase III Success, and Robust Catalyst Flow Underpin Buy Rating
PremiumRatings
Ionis Pharmaceuticals: Advancing Pipeline, HBV Phase III Success, and Robust Catalyst Flow Underpin Buy Rating
7d ago
IONS
Ionis partner GSK reports B-Well 1, B-Well 2 trials meet primary endpoint
PremiumThe Fly
Ionis partner GSK reports B-Well 1, B-Well 2 trials meet primary endpoint
7d ago
GSK
IONS
Ionis Buy Rating Reiterated as Analyst Cites Tryngolza’s Competitive Moat and Confirms Unchanged $125 Price Target
PremiumRatings
Ionis Buy Rating Reiterated as Analyst Cites Tryngolza’s Competitive Moat and Confirms Unchanged $125 Price Target
8d ago
IONS
Citi Names 2 Biotech Stocks ‘Top Picks’ for 2026
PremiumMarket NewsCiti Names 2 Biotech Stocks ‘Top Picks’ for 2026
11d ago
CYTK
IONS
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
Premium
The Fly
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
16d ago
AMT
BAP
Ionis Pharmaceuticals initiated with a Buy, named a top pick at Citi
Premium
The Fly
Ionis Pharmaceuticals initiated with a Buy, named a top pick at Citi
16d ago
IONS
Ionis Pharmaceuticals: Buy Rating Reaffirmed as Alzheimer’s Program Advances and Price Target Raised to $111 from $100
PremiumRatings
Ionis Pharmaceuticals: Buy Rating Reaffirmed as Alzheimer’s Program Advances and Price Target Raised to $111 from $100
20d ago
IONS
Pelacarsen Phase 3 HORIZON Trial Seen as Key Catalyst Supporting Ionis Buy Rating and Unchanged $105 Price Target
PremiumRatings
Pelacarsen Phase 3 HORIZON Trial Seen as Key Catalyst Supporting Ionis Buy Rating and Unchanged $105 Price Target
20d ago
IONS
Ionis Pharmaceuticals participates in a conference call with Cantor
PremiumThe Fly
Ionis Pharmaceuticals participates in a conference call with Cantor
20d ago
IONS
Biogen’s diranersen shows benefits in early Alzheimer’s Disease
PremiumThe Fly
Biogen’s diranersen shows benefits in early Alzheimer’s Disease
21d ago
BIIB
IONS
Ionis announces Biogen’s CELIA study did not meet primary endpoint
PremiumThe FlyIonis announces Biogen’s CELIA study did not meet primary endpoint
21d ago
BIIB
IONS
Ionis Pharmaceuticals price target raised to $111 from $104 at Oppenheimer
Premium
The Fly
Ionis Pharmaceuticals price target raised to $111 from $104 at Oppenheimer
1M ago
IONS
Ionis Pharmaceuticals price target raised to $86 from $83 at Stifel
Premium
The Fly
Ionis Pharmaceuticals price target raised to $86 from $83 at Stifel
1M ago
IONS
Ionis Pharmaceuticals price target raised to $100 from $95 at RBC Capital
PremiumThe Fly
Ionis Pharmaceuticals price target raised to $100 from $95 at RBC Capital
1M ago
IONS
Ionis Pharmaceuticals price target raised to $125 from $120 at H.C. Wainwright
PremiumThe Fly
Ionis Pharmaceuticals price target raised to $125 from $120 at H.C. Wainwright
1M ago
IONS
Ionis Pharmaceuticals price target raised to $115 from $106 at Barclays
PremiumThe Fly
Ionis Pharmaceuticals price target raised to $115 from $106 at Barclays
1M ago
IONS
Ionis Pharmaceuticals’ Earnings Call Flags Growth and Risks
PremiumCompany Announcements
Ionis Pharmaceuticals’ Earnings Call Flags Growth and Risks
1M ago
IONS
Analyst Reiterates Buy Rating on Ionis Pharmaceuticals, Maintains $105 Price Target on Strong Q1 and Upgraded Olezarsen Outlook
PremiumRatingsAnalyst Reiterates Buy Rating on Ionis Pharmaceuticals, Maintains $105 Price Target on Strong Q1 and Upgraded Olezarsen Outlook
1M ago
IONS
Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c)
Premium
The Fly
Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c)
1M ago
IONS
Ionis Pharmaceuticals raises FY26 revenue view $875M-$900M from $800M-$825M
Premium
The Fly
Ionis Pharmaceuticals raises FY26 revenue view $875M-$900M from $800M-$825M
1M ago
IONS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >